Leadership

Leadership

Our success is rooted in passion and perseverance, and is backed by rigorous science. We have brought together accomplished experts in immunotherapy and operational excellence to contribute their knowledge in a practical and efficient way. Our corporate culture encourages people to contribute their unique and diverse perspectives, to leverage their unrelenting optimism and creativity, and to be ready to learn and develop solutions together towards a common and greater purpose.

Board of Directors


Ryan Saadi, MD, MPH

Chairman and Chief Executive Officer

View Bio

Kevin McGrath

Chief Operating Officer

View Bio

Kirti Desai

Chief Financial Officer

Dr. Curtis Patton

View Bio

Advisory Board


Neal Flomenberg Thomas Jefferson University Sidney Kimmel Cancer Center Bone Marrow Transplant Cell Therapy Expert

Neal Flomenberg, MD

Chairman, Advisory Board

View Bio
Bruce Cooper Global Medical Affairs Global Commercialization Pharmaceutical Biotech

Dr. Bruce Cooper

Member, Advisory Board

View Bio

Manmohan Patel, MD

Member, Advisory Board

View Bio

Innovation and Public Health Council


Himanshu Patel

Himanshu Patel, MD

Chairman, Innovation and Public Health Council

Our Team Leadership


Ryan Saadi, MD, MPH

Chief Executive Officer

View Bio

Kirti Desai

Chief Financial Officer

Kevin McGrath

Chief Operating Officer

View Bio
Tommy Joyce promising curative T cell therapy for COVID-19 Deputy Assistant Secretary (DAS) White House U.S. Senate

Tommy Joyce

Government and Investor Relations

View Bio
Carla Angel

Carla Angel

Project Management and Public Relations

Emerging Leaders Program


Our global healthcare system is dependent on continuous medical innovation. The goal of our Emerging Leaders Program is to develop the next generation of Biopharma leaders who will revolutionize how we think about and tackle our greatest health challenges. Please join us in welcoming our first group of Emerging Leaders.

Sophie

Vassar College

Rusheil

Kansas City University of Medicine

Emily

Yale University

© 2021 Tevogen Bio. All Rights Reserved.

Ryan Saadi, M.D., M.P.H., is Chief Executive Officer and founder of Tevogen Bio. Ryan also serves as Managing Director and Executive Advisor of the Center for Market Access and Medical Innovation, a cross-sector educational initiative which seeks to promote sustainable medical innovation, improve patient access, inform policy-making, and foster talent development.

As a renowned innovator in the world of healthcare and a leading expert in global health policy, market access, clinical development, and research, Ryan actively partners, speaks and advises on various healthcare matters with a number of organizations from the private sector (life sciences companies), the public sector (including at the state, federal and global level), academia, and the not-for-profit sectors.

Ryan points to his unyielding passion for public health, his unique ability to unite normally siloed parties under a common cause, and his “irrational optimism” as the driving force behind his success and the recent formation of Tevogen Bio.

Previously, Ryan spent nearly three decades in healthcare, in leadership roles within hospital administration, managed care, and life sciences. He has been recognized multiple times for his unique leadership approach, including being named among the Most Inspiring Leaders in the Life Sciences Industry. Ryan is an accomplished graduate of Harvard Business School Executive Education Program, Yale School of Medicine, and Dhaka Medical College.

Mr. McGrath has 25 years of experience helping biopharmaceutical companies develop and enhance their market access and value evidence capabilities to support the launch of innovative medicines. He is a graduate of Princeton University.

In addition to his professional experience, Mr. McGrath is dedicated to volunteerism, providing educational, athletic and cultural enrichment opportunities to youth and underserved communities. He is inspired by Tevogen’s mission of developing curative therapies at an affordable price and it’s potential to dramatically improve the global public health landscape.

Dr. Curtis Patton, Professor Emeritus at Yale University, is a world renowned scientist and Public Health expert. He has served in a variety of administrative capacities including Division Head, Epidemiology of Microbial Diseases and Acting Head of Global Health. He has also served as the Director of International Medical Studies and Chair of the Committee on International Health at Yale University.

Dr. Flomenberg is Professor and Chair of the Department of Medical Oncology and Deputy Director of Jefferson’s Sidney Kimmel Cancer Center. His career has focused on the care of patients with blood cancers, particularly those undergoing bone marrow or peripheral blood stem cell transplants. His laboratory and clinical research efforts have focused on improving our understanding of the challenges these patients face and developing innovative solutions to these problems. He has authored more than 175 peer reviewed publications.

Amongst others, his most significant scientific accomplishments include:

  • The first in human administration of Interleukin-2
  • Initial descriptions of immunologic recovery after allogeneic BMT including the first description of the spectratyping technique to assess T cell receptor diversity
  • The initial reports describing the mechanisms of immunologic tolerance after mismatched human bone marrow transplantation.
  • One of the earliest reports on the utility of the adoptive transfer of donor lymphocytes for control of residual/relapsed malignancy after allogeneic transplantation.
  • Establishment of a reproducible platform for haploidentical transplantation which allowed T cell and stem cell dose to be consistently controlled and manipulated for therapeutic advantage.

His laboratory work was focused on cellular immunology, immunogenetics, and histocompatibility. He served as the organizer/leader of the cellular section of the Tenth International Histocompatibility Workshop.

In addition to his research, Dr. Flomenberg maintains an active practice and has been continuously listed in Philadelphia Magazine’s Top Doctors in Philadelphia and Castle Connolly’s America’s Top Doctors over the last 15 years. Under his leadership, Jefferson’s Department of Medical Oncology more than tripled in size, established a nationally recognized senior adult oncology program as well as an embedded Supportive Medicine and Survivorship Program, and has launched efforts to expand home chemotherapy administration and other cutting-edge care delivery models.

Dr. Flomenberg has been the recipient of numerous awards including:

  • The Simon Gratz Award for Research Most Likely to influence Patient Care – 2003
  • The Leukemia Lymphoma Society Contributions to Mankind Award – 2006
  • The Pennsylvania State University Outstanding Science Alumnus Award – 2006
  • He was the inaugural recipient of the Philadelphia Chapter of the Leukemia Lymphoma Society’s Lifetime Achievement Award in 2018
  • Thomas Jefferson University’s Alumnus of the Year Award 2019

Dr. Bruce Cooper is biopharma physician-leader and entrepreneur with decades of experience in US and Global Medical Affairs, drug/device development, reimbursement and commercialization. Bruce has demonstrated success in start-up, specialty and large Pharma across a broad range of therapeutic areas and has been particularly instrumental in developing high performing leaders and organizations with a bias for action and innovation.

Bruce is currently Managing Director of VIANZUS LLC, a consulting company. Prior to this, his distinguished career highlights include various leadership roles in medical affairs, company general management, strategic marketing, clinical development and regulatory affairs, pricing and reimbursement, business development and change management at global companies like AstraZeneca, Roche/Genentech, CorMedix, the Medicines Company, and Sanofi Aventis.

Bruce continues to use his skills and expertise advising companies who aim to bring transformative therapies to patients and is very excited about the potential for cytotoxic CD8+ T lymphocytes to cure serious infection and other diseases like cancer.

Privately, as a resident of New York City, Bruce is a passionate supporter of the arts as a Patron of the Metropolitan Opera, New York Philharmonic and a number of Off-Broadway theaters. He also enjoys the challenge of growing tropical plants on his Manhattan terrace.

Bruce received his Medical Training and Degrees (MBChB, BHB) and post graduate training in clinical microbiology at University of Auckland Medical School in New Zealand.

Manmohan Patel, MD is a prominent pulmonary and critical care specialist with nearly 50 years of medical expertise in a diverse field of specialties, including pulmonary, internal, geriatric and emergency medicine as well as critical care. Dr. Patel’s commitment to community and medical management is demonstrated by his distinguished appointments, including serving as the Director of Post Cardiac Surgery at Saint Michael’s Medical Center in Newark, NJ and as Chairman of the Department of Medicine at Meadowlands Hospital Medical Center in Secaucus, NJ. In 2000, he was appointed by the Governor of New Jersey to the Board of Medical Examiners Executive Committee for the state and served on various other committees in that capacity.

Tommy Joyce, M.B.A., leads government affairs and investor relations for Tevogen Bio, which currently is seeking to introduce its promising curative T cell therapy for COVID-19 to markets as its first of many planned curative therapies using its unique processes and patents. Previously, Joyce was the Deputy Assistant Secretary (DAS) for Global Energy Security and Multilateral Engagement, and acting DAS for Market Development and Energy Innovation at the U.S. Department of Energy. In this position he focused on transitioning the U.S. strategic posture from that of a net importing country, to one poised to compete and support the energy security of allies and partners as a net energy exporter, including through open rules-based global markets and strengthened international partnerships.

Joyce is a national security leader with extensive interagency and international policy experience on the United States’ most pressing issues. He is skilled in the development of international coalitions to solve strategic problems, negotiation of significant bilateral and multilateral outcomes, and development and execution of international strategies. He served as Senior Advisor for Defense Nuclear Nonproliferation in the National Nuclear Security Administration. While a consultant he served in several capacities including program manager, foreign liaison, strategic assessments author, and risk/project manager. Also in his career, Joyce served in the State Department’s Office of the Special Envoy for Nuclear Energy and Nonproliferation, White House National Security Council’s Office of International Economics, the U.S. Senate Majority Leader’s Office, and U.S. House of Representatives.

Tommy Joyce, M.B.A., leads government affairs and investor relations for Tevogen Bio, which currently is seeking to introduce its promising curative T cell therapy for COVID-19 to markets as its first of many planned curative therapies using its unique processes and patents. Previously, Joyce was the Deputy Assistant Secretary (DAS) for Global Energy Security and Multilateral Engagement, and acting DAS for Market Development and Energy Innovation at the U.S. Department of Energy. In this position he focused on transitioning the U.S. strategic posture from that of a net importing country, to one poised to compete and support the energy security of allies and partners as a net energy exporter, including through open rules-based global markets and strengthened international partnerships.

Joyce is a national security leader with extensive interagency and international policy experience on the United States’ most pressing issues. He is skilled in the development of international coalitions to solve strategic problems, negotiation of significant bilateral and multilateral outcomes, and development and execution of international strategies. He served as Senior Advisor for Defense Nuclear Nonproliferation in the National Nuclear Security Administration. While a consultant he served in several capacities including program manager, foreign liaison, strategic assessments author, and risk/project manager. Also in his career, Joyce served in the State Department’s Office of the Special Envoy for Nuclear Energy and Nonproliferation, White House National Security Council’s Office of International Economics, the U.S. Senate Majority Leader’s Office, and U.S. House of Representatives.

Manmohan Patel, MD is a prominent pulmonary and critical care specialist with nearly 50 years of medical expertise in a diverse field of specialties, including pulmonary, internal, geriatric and emergency medicine as well as critical care. Dr. Patel’s commitment to community and medical management is demonstrated by his distinguished appointments, including serving as the Director of Post Cardiac Surgery at Saint Michael’s Medical Center in Newark, NJ and as Chairman of the Department of Medicine at Meadowlands Hospital Medical Center in Secaucus, NJ. In 2000, he was appointed by the Governor of New Jersey to the Board of Medical Examiners Executive Committee for the state and served on various other committees in that capacity.

Tommy Joyce, M.B.A., leads government affairs and investor relations for Tevogen Bio, which currently is seeking to introduce its promising curative T cell therapy for COVID-19 to markets as its first of many planned curative therapies using its unique processes and patents. Previously, Joyce was the Deputy Assistant Secretary (DAS) for Global Energy Security and Multilateral Engagement, and acting DAS for Market Development and Energy Innovation at the U.S. Department of Energy. In this position he focused on transitioning the U.S. strategic posture from that of a net importing country, to one poised to compete and support the energy security of allies and partners as a net energy exporter, including through open rules-based global markets and strengthened international partnerships.

Joyce is a national security leader with extensive interagency and international policy experience on the United States’ most pressing issues. He is skilled in the development of international coalitions to solve strategic problems, negotiation of significant bilateral and multilateral outcomes, and development and execution of international strategies. He served as Senior Advisor for Defense Nuclear Nonproliferation in the National Nuclear Security Administration. While a consultant he served in several capacities including program manager, foreign liaison, strategic assessments author, and risk/project manager. Also in his career, Joyce served in the State Department’s Office of the Special Envoy for Nuclear Energy and Nonproliferation, White House National Security Council’s Office of International Economics, the U.S. Senate Majority Leader’s Office, and U.S. House of Representatives.

Dr. Bruce Cooper is biopharma physician-leader and entrepreneur with decades of experience in US and Global Medical Affairs, drug/device development, reimbursement and commercialization. Bruce has demonstrated success in start-up, specialty and large Pharma across a broad range of therapeutic areas and has been particularly instrumental in developing high performing leaders and organizations with a bias for action and innovation.

Bruce is currently Managing Director of VIANZUS LLC, a consulting company. Prior to this, his distinguished career highlights include various leadership roles in medical affairs, company general management, strategic marketing, clinical development and regulatory affairs, pricing and reimbursement, business development and change management at global companies like AstraZeneca, Roche/Genentech, CorMedix, the Medicines Company, and Sanofi Aventis.

Bruce continues to use his skills and expertise advising companies who aim to bring transformative therapies to patients and is very excited about the potential for cytotoxic CD8+ T lymphocytes to cure serious infection and other diseases like cancer.

Privately, as a resident of New York City, Bruce is a passionate supporter of the arts as a Patron of the Metropolitan Opera, New York Philharmonic and a number of Off-Broadway theaters. He also enjoys the challenge of growing tropical plants on his Manhattan terrace.

Bruce received his Medical Training and Degrees (MBChB, BHB) and post graduate training in clinical microbiology at University of Auckland Medical School in New Zealand.

Manmohan Patel, MD is a prominent pulmonary and critical care specialist with nearly 50 years of medical expertise in a diverse field of specialties, including pulmonary, internal, geriatric and emergency medicine as well as critical care. Dr. Patel’s commitment to community and medical management is demonstrated by his distinguished appointments, including serving as the Director of Post Cardiac Surgery at Saint Michael’s Medical Center in Newark, NJ and as Chairman of the Department of Medicine at Meadowlands Hospital Medical Center in Secaucus, NJ. In 2000, he was appointed by the Governor of New Jersey to the Board of Medical Examiners Executive Committee for the state and served on various other committees in that capacity.

Tommy Joyce, M.B.A., leads government affairs and investor relations for Tevogen Bio, which currently is seeking to introduce its promising curative T cell therapy for COVID-19 to markets as its first of many planned curative therapies using its unique processes and patents. Previously, Joyce was the Deputy Assistant Secretary (DAS) for Global Energy Security and Multilateral Engagement, and acting DAS for Market Development and Energy Innovation at the U.S. Department of Energy. In this position he focused on transitioning the U.S. strategic posture from that of a net importing country, to one poised to compete and support the energy security of allies and partners as a net energy exporter, including through open rules-based global markets and strengthened international partnerships.

Joyce is a national security leader with extensive interagency and international policy experience on the United States’ most pressing issues. He is skilled in the development of international coalitions to solve strategic problems, negotiation of significant bilateral and multilateral outcomes, and development and execution of international strategies. He served as Senior Advisor for Defense Nuclear Nonproliferation in the National Nuclear Security Administration. While a consultant he served in several capacities including program manager, foreign liaison, strategic assessments author, and risk/project manager. Also in his career, Joyce served in the State Department’s Office of the Special Envoy for Nuclear Energy and Nonproliferation, White House National Security Council’s Office of International Economics, the U.S. Senate Majority Leader’s Office, and U.S. House of Representatives.

Dr. Flomenberg is Professor and Chair of the Department of Medical Oncology and Deputy Director of Jefferson’s Sidney Kimmel Cancer Center. His career has focused on the care of patients with blood cancers, particularly those undergoing bone marrow or peripheral blood stem cell transplants. His laboratory and clinical research efforts have focused on improving our understanding of the challenges these patients face and developing innovative solutions to these problems. He has authored more than 175 peer reviewed publications.

Amongst others, his most significant scientific accomplishments include:

  • The first in human administration of Interleukin-2
  • Initial descriptions of immunologic recovery after allogeneic BMT including the first description of the spectratyping technique to assess T cell receptor diversity
  • The initial reports describing the mechanisms of immunologic tolerance after mismatched human bone marrow transplantation.
  • One of the earliest reports on the utility of the adoptive transfer of donor lymphocytes for control of residual/relapsed malignancy after allogeneic transplantation.
  • Establishment of a reproducible platform for haploidentical transplantation which allowed T cell and stem cell dose to be consistently controlled and manipulated for therapeutic advantage.

His laboratory work was focused on cellular immunology, immunogenetics, and histocompatibility. He served as the organizer/leader of the cellular section of the Tenth International Histocompatibility Workshop.

In addition to his research, Dr. Flomenberg maintains an active practice and has been continuously listed in Philadelphia Magazine’s Top Doctors in Philadelphia and Castle Connolly’s America’s Top Doctors over the last 15 years. Under his leadership, Jefferson’s Department of Medical Oncology more than tripled in size, established a nationally recognized senior adult oncology program as well as an embedded Supportive Medicine and Survivorship Program, and has launched efforts to expand home chemotherapy administration and other cutting-edge care delivery models.

Dr. Flomenberg has been the recipient of numerous awards including:

  • The Simon Gratz Award for Research Most Likely to influence Patient Care – 2003
  • The Leukemia Lymphoma Society Contributions to Mankind Award – 2006
  • The Pennsylvania State University Outstanding Science Alumnus Award – 2006
  • He was the inaugural recipient of the Philadelphia Chapter of the Leukemia Lymphoma Society’s Lifetime Achievement Award in 2018
  • Thomas Jefferson University’s Alumnus of the Year Award 2019

Dr. Bruce Cooper is biopharma physician-leader and entrepreneur with decades of experience in US and Global Medical Affairs, drug/device development, reimbursement and commercialization. Bruce has demonstrated success in start-up, specialty and large Pharma across a broad range of therapeutic areas and has been particularly instrumental in developing high performing leaders and organizations with a bias for action and innovation.

Bruce is currently Managing Director of VIANZUS LLC, a consulting company. Prior to this, his distinguished career highlights include various leadership roles in medical affairs, company general management, strategic marketing, clinical development and regulatory affairs, pricing and reimbursement, business development and change management at global companies like AstraZeneca, Roche/Genentech, CorMedix, the Medicines Company, and Sanofi Aventis.

Bruce continues to use his skills and expertise advising companies who aim to bring transformative therapies to patients and is very excited about the potential for cytotoxic CD8+ T lymphocytes to cure serious infection and other diseases like cancer.

Privately, as a resident of New York City, Bruce is a passionate supporter of the arts as a Patron of the Metropolitan Opera, New York Philharmonic and a number of Off-Broadway theaters. He also enjoys the challenge of growing tropical plants on his Manhattan terrace.

Bruce received his Medical Training and Degrees (MBChB, BHB) and post graduate training in clinical microbiology at University of Auckland Medical School in New Zealand.

Manmohan Patel, MD is a prominent pulmonary and critical care specialist with nearly 50 years of medical expertise in a diverse field of specialties, including pulmonary, internal, geriatric and emergency medicine as well as critical care. Dr. Patel’s commitment to community and medical management is demonstrated by his distinguished appointments, including serving as the Director of Post Cardiac Surgery at Saint Michael’s Medical Center in Newark, NJ and as Chairman of the Department of Medicine at Meadowlands Hospital Medical Center in Secaucus, NJ. In 2000, he was appointed by the Governor of New Jersey to the Board of Medical Examiners Executive Committee for the state and served on various other committees in that capacity.

Tommy Joyce, M.B.A., leads government affairs and investor relations for Tevogen Bio, which currently is seeking to introduce its promising curative T cell therapy for COVID-19 to markets as its first of many planned curative therapies using its unique processes and patents. Previously, Joyce was the Deputy Assistant Secretary (DAS) for Global Energy Security and Multilateral Engagement, and acting DAS for Market Development and Energy Innovation at the U.S. Department of Energy. In this position he focused on transitioning the U.S. strategic posture from that of a net importing country, to one poised to compete and support the energy security of allies and partners as a net energy exporter, including through open rules-based global markets and strengthened international partnerships.

Joyce is a national security leader with extensive interagency and international policy experience on the United States’ most pressing issues. He is skilled in the development of international coalitions to solve strategic problems, negotiation of significant bilateral and multilateral outcomes, and development and execution of international strategies. He served as Senior Advisor for Defense Nuclear Nonproliferation in the National Nuclear Security Administration. While a consultant he served in several capacities including program manager, foreign liaison, strategic assessments author, and risk/project manager. Also in his career, Joyce served in the State Department’s Office of the Special Envoy for Nuclear Energy and Nonproliferation, White House National Security Council’s Office of International Economics, the U.S. Senate Majority Leader’s Office, and U.S. House of Representatives.

Dr. Curtis Patton, Professor Emeritus at Yale University, is a world renowned scientist and Public Health expert. He has served in a variety of administrative capacities including Division Head, Epidemiology of Microbial Diseases and Acting Head of Global Health. He has also served as the Director of International Medical Studies and Chair of the Committee on International Health at Yale University.

Dr. Flomenberg is Professor and Chair of the Department of Medical Oncology and Deputy Director of Jefferson’s Sidney Kimmel Cancer Center. His career has focused on the care of patients with blood cancers, particularly those undergoing bone marrow or peripheral blood stem cell transplants. His laboratory and clinical research efforts have focused on improving our understanding of the challenges these patients face and developing innovative solutions to these problems. He has authored more than 175 peer reviewed publications.

Amongst others, his most significant scientific accomplishments include:

  • The first in human administration of Interleukin-2
  • Initial descriptions of immunologic recovery after allogeneic BMT including the first description of the spectratyping technique to assess T cell receptor diversity
  • The initial reports describing the mechanisms of immunologic tolerance after mismatched human bone marrow transplantation.
  • One of the earliest reports on the utility of the adoptive transfer of donor lymphocytes for control of residual/relapsed malignancy after allogeneic transplantation.
  • Establishment of a reproducible platform for haploidentical transplantation which allowed T cell and stem cell dose to be consistently controlled and manipulated for therapeutic advantage.

His laboratory work was focused on cellular immunology, immunogenetics, and histocompatibility. He served as the organizer/leader of the cellular section of the Tenth International Histocompatibility Workshop.

In addition to his research, Dr. Flomenberg maintains an active practice and has been continuously listed in Philadelphia Magazine’s Top Doctors in Philadelphia and Castle Connolly’s America’s Top Doctors over the last 15 years. Under his leadership, Jefferson’s Department of Medical Oncology more than tripled in size, established a nationally recognized senior adult oncology program as well as an embedded Supportive Medicine and Survivorship Program, and has launched efforts to expand home chemotherapy administration and other cutting-edge care delivery models.

Dr. Flomenberg has been the recipient of numerous awards including:

  • The Simon Gratz Award for Research Most Likely to influence Patient Care – 2003
  • The Leukemia Lymphoma Society Contributions to Mankind Award – 2006
  • The Pennsylvania State University Outstanding Science Alumnus Award – 2006
  • He was the inaugural recipient of the Philadelphia Chapter of the Leukemia Lymphoma Society’s Lifetime Achievement Award in 2018
  • Thomas Jefferson University’s Alumnus of the Year Award 2019

Dr. Bruce Cooper is biopharma physician-leader and entrepreneur with decades of experience in US and Global Medical Affairs, drug/device development, reimbursement and commercialization. Bruce has demonstrated success in start-up, specialty and large Pharma across a broad range of therapeutic areas and has been particularly instrumental in developing high performing leaders and organizations with a bias for action and innovation.

Bruce is currently Managing Director of VIANZUS LLC, a consulting company. Prior to this, his distinguished career highlights include various leadership roles in medical affairs, company general management, strategic marketing, clinical development and regulatory affairs, pricing and reimbursement, business development and change management at global companies like AstraZeneca, Roche/Genentech, CorMedix, the Medicines Company, and Sanofi Aventis.

Bruce continues to use his skills and expertise advising companies who aim to bring transformative therapies to patients and is very excited about the potential for cytotoxic CD8+ T lymphocytes to cure serious infection and other diseases like cancer.

Privately, as a resident of New York City, Bruce is a passionate supporter of the arts as a Patron of the Metropolitan Opera, New York Philharmonic and a number of Off-Broadway theaters. He also enjoys the challenge of growing tropical plants on his Manhattan terrace.

Bruce received his Medical Training and Degrees (MBChB, BHB) and post graduate training in clinical microbiology at University of Auckland Medical School in New Zealand.

Manmohan Patel, MD is a prominent pulmonary and critical care specialist with nearly 50 years of medical expertise in a diverse field of specialties, including pulmonary, internal, geriatric and emergency medicine as well as critical care. Dr. Patel’s commitment to community and medical management is demonstrated by his distinguished appointments, including serving as the Director of Post Cardiac Surgery at Saint Michael’s Medical Center in Newark, NJ and as Chairman of the Department of Medicine at Meadowlands Hospital Medical Center in Secaucus, NJ. In 2000, he was appointed by the Governor of New Jersey to the Board of Medical Examiners Executive Committee for the state and served on various other committees in that capacity.

Tommy Joyce, M.B.A., leads government affairs and investor relations for Tevogen Bio, which currently is seeking to introduce its promising curative T cell therapy for COVID-19 to markets as its first of many planned curative therapies using its unique processes and patents. Previously, Joyce was the Deputy Assistant Secretary (DAS) for Global Energy Security and Multilateral Engagement, and acting DAS for Market Development and Energy Innovation at the U.S. Department of Energy. In this position he focused on transitioning the U.S. strategic posture from that of a net importing country, to one poised to compete and support the energy security of allies and partners as a net energy exporter, including through open rules-based global markets and strengthened international partnerships.

Joyce is a national security leader with extensive interagency and international policy experience on the United States’ most pressing issues. He is skilled in the development of international coalitions to solve strategic problems, negotiation of significant bilateral and multilateral outcomes, and development and execution of international strategies. He served as Senior Advisor for Defense Nuclear Nonproliferation in the National Nuclear Security Administration. While a consultant he served in several capacities including program manager, foreign liaison, strategic assessments author, and risk/project manager. Also in his career, Joyce served in the State Department’s Office of the Special Envoy for Nuclear Energy and Nonproliferation, White House National Security Council’s Office of International Economics, the U.S. Senate Majority Leader’s Office, and U.S. House of Representatives.

Mr. McGrath has 25 years of experience helping biopharmaceutical companies develop and enhance their market access and value evidence capabilities to support the launch of innovative medicines. He is a graduate of Princeton University.

In addition to his professional experience, Mr. McGrath is dedicated to volunteerism, providing educational, athletic and cultural enrichment opportunities to youth and underserved communities. He is inspired by Tevogen’s mission of developing curative therapies at an affordable price and it’s potential to dramatically improve the global public health landscape.

Dr. Curtis Patton, Professor Emeritus at Yale University, is a world renowned scientist and Public Health expert. He has served in a variety of administrative capacities including Division Head, Epidemiology of Microbial Diseases and Acting Head of Global Health. He has also served as the Director of International Medical Studies and Chair of the Committee on International Health at Yale University.

Dr. Flomenberg is Professor and Chair of the Department of Medical Oncology and Deputy Director of Jefferson’s Sidney Kimmel Cancer Center. His career has focused on the care of patients with blood cancers, particularly those undergoing bone marrow or peripheral blood stem cell transplants. His laboratory and clinical research efforts have focused on improving our understanding of the challenges these patients face and developing innovative solutions to these problems. He has authored more than 175 peer reviewed publications.

Amongst others, his most significant scientific accomplishments include:

  • The first in human administration of Interleukin-2
  • Initial descriptions of immunologic recovery after allogeneic BMT including the first description of the spectratyping technique to assess T cell receptor diversity
  • The initial reports describing the mechanisms of immunologic tolerance after mismatched human bone marrow transplantation.
  • One of the earliest reports on the utility of the adoptive transfer of donor lymphocytes for control of residual/relapsed malignancy after allogeneic transplantation.
  • Establishment of a reproducible platform for haploidentical transplantation which allowed T cell and stem cell dose to be consistently controlled and manipulated for therapeutic advantage.

His laboratory work was focused on cellular immunology, immunogenetics, and histocompatibility. He served as the organizer/leader of the cellular section of the Tenth International Histocompatibility Workshop.

In addition to his research, Dr. Flomenberg maintains an active practice and has been continuously listed in Philadelphia Magazine’s Top Doctors in Philadelphia and Castle Connolly’s America’s Top Doctors over the last 15 years. Under his leadership, Jefferson’s Department of Medical Oncology more than tripled in size, established a nationally recognized senior adult oncology program as well as an embedded Supportive Medicine and Survivorship Program, and has launched efforts to expand home chemotherapy administration and other cutting-edge care delivery models.

Dr. Flomenberg has been the recipient of numerous awards including:

  • The Simon Gratz Award for Research Most Likely to influence Patient Care – 2003
  • The Leukemia Lymphoma Society Contributions to Mankind Award – 2006
  • The Pennsylvania State University Outstanding Science Alumnus Award – 2006
  • He was the inaugural recipient of the Philadelphia Chapter of the Leukemia Lymphoma Society’s Lifetime Achievement Award in 2018
  • Thomas Jefferson University’s Alumnus of the Year Award 2019

Dr. Bruce Cooper is biopharma physician-leader and entrepreneur with decades of experience in US and Global Medical Affairs, drug/device development, reimbursement and commercialization. Bruce has demonstrated success in start-up, specialty and large Pharma across a broad range of therapeutic areas and has been particularly instrumental in developing high performing leaders and organizations with a bias for action and innovation.

Bruce is currently Managing Director of VIANZUS LLC, a consulting company. Prior to this, his distinguished career highlights include various leadership roles in medical affairs, company general management, strategic marketing, clinical development and regulatory affairs, pricing and reimbursement, business development and change management at global companies like AstraZeneca, Roche/Genentech, CorMedix, the Medicines Company, and Sanofi Aventis.

Bruce continues to use his skills and expertise advising companies who aim to bring transformative therapies to patients and is very excited about the potential for cytotoxic CD8+ T lymphocytes to cure serious infection and other diseases like cancer.

Privately, as a resident of New York City, Bruce is a passionate supporter of the arts as a Patron of the Metropolitan Opera, New York Philharmonic and a number of Off-Broadway theaters. He also enjoys the challenge of growing tropical plants on his Manhattan terrace.

Bruce received his Medical Training and Degrees (MBChB, BHB) and post graduate training in clinical microbiology at University of Auckland Medical School in New Zealand.

Manmohan Patel, MD is a prominent pulmonary and critical care specialist with nearly 50 years of medical expertise in a diverse field of specialties, including pulmonary, internal, geriatric and emergency medicine as well as critical care. Dr. Patel’s commitment to community and medical management is demonstrated by his distinguished appointments, including serving as the Director of Post Cardiac Surgery at Saint Michael’s Medical Center in Newark, NJ and as Chairman of the Department of Medicine at Meadowlands Hospital Medical Center in Secaucus, NJ. In 2000, he was appointed by the Governor of New Jersey to the Board of Medical Examiners Executive Committee for the state and served on various other committees in that capacity.

Tommy Joyce, M.B.A., leads government affairs and investor relations for Tevogen Bio, which currently is seeking to introduce its promising curative T cell therapy for COVID-19 to markets as its first of many planned curative therapies using its unique processes and patents. Previously, Joyce was the Deputy Assistant Secretary (DAS) for Global Energy Security and Multilateral Engagement, and acting DAS for Market Development and Energy Innovation at the U.S. Department of Energy. In this position he focused on transitioning the U.S. strategic posture from that of a net importing country, to one poised to compete and support the energy security of allies and partners as a net energy exporter, including through open rules-based global markets and strengthened international partnerships.

Joyce is a national security leader with extensive interagency and international policy experience on the United States’ most pressing issues. He is skilled in the development of international coalitions to solve strategic problems, negotiation of significant bilateral and multilateral outcomes, and development and execution of international strategies. He served as Senior Advisor for Defense Nuclear Nonproliferation in the National Nuclear Security Administration. While a consultant he served in several capacities including program manager, foreign liaison, strategic assessments author, and risk/project manager. Also in his career, Joyce served in the State Department’s Office of the Special Envoy for Nuclear Energy and Nonproliferation, White House National Security Council’s Office of International Economics, the U.S. Senate Majority Leader’s Office, and U.S. House of Representatives.